FDAnews Device Daily Bulletin

Slowed uptake of the Sapien transcatheter heart valve led Edwards Lifesciences to issue advance warning last week of disappointing third-quarter sales. Edwards’ transcatheter heart valve sales dropped to $124 million globally and $55 million in the U.S., compared with $145 million and $62 million, respectively, in the second quarter.
Devices & Diagnostics Letter